Building on an established reputation in the area of deal negotiation and valuation, we are pleased to announce the release of the revised, best-selling Industry Standard Report.
This important Report takes into account all recent developments and focuses on the issues of most concern to business development and licensing professionals within the large pharmaceutical, biotechnology and academic network. It fully addresses financial modelling and provides detailed valuation examples. Its content has been formulated and thoroughly tested.
The Report will:
- Provide a thorough understanding of robust valuation methodologies - Enable more rigorous economic portfolio analysis - Offer greater transparency in portfolio analysis - Assist the formulation of attractive deal structures - Permit accurate comparison of alternative deals - Highlight the value creation process - Minimise risk in future deals
It is an essential reference source for all those aiming to maximise deal values and minimise risk.
